The 2019 Clinical Practice Guidelines by the European Society of Cardiology (ESC) on DM recommend either SGLT2 inhibitors or glucagon-like peptide‐1 receptor agonists (GLP‐1 RAs) in patients with DM2 and established atherosclerotic cardiovascular disease or in case of very high/high cardiovascular risk (e.g. ≥ 3 major risk factors or DM duration ≥ 10 years), to reduce cardiovascular events [18]. Here, SLC5A2 is linked to myotonic dystrophy type 2.